57076-71-8 Usage
Description
Denbufylline is a cell-permeable xanthine derivative that functions as a selective inhibitor of phosphodiesterase IV (PDE IV). It is characterized by its bronchodilatory properties and its ability to display a negative inotropic effect by acting on a verapamil-sensitive site of the calcium channel in guinea pig ventricular papillary muscle, independently of its PDE inhibitory activity. Denbufylline also has vasodilatory effects on cerebral vessels and can potently activate the hypothalamic-pituitary-adrenal axis. As a PDE4 inhibitor, it plays a significant role in the regulation of cyclic adenosine monophosphate (cAMP) in tissues related to the central nervous and immune systems.
Uses
Used in Pharmaceutical Industry:
Denbufylline is used as a bronchial spasmolysis agent for its bronchodilatory properties, which can help in treating conditions associated with constricted airways, such as asthma and chronic obstructive pulmonary disease (COPD).
Used in Central Nervous System Applications:
Denbufylline is used as a therapeutic agent for its effects on the central nervous system, particularly in the treatment of Alzheimer's disease (AD) and vascular dementia (VaD). Although studies have shown no significant differences compared to placebo, patients treated with denbufylline have tended to improve their cognitive scores.
Used in Immune System Applications:
Denbufylline is used as a modulator of the immune system due to its role as a PDE4 inhibitor, which can influence the tissue distribution related to the immune system. This property makes it a potential candidate for the development of treatments targeting immune-related pathologies.
Chemical Properties:
Denbufylline is a white solid with specific chemical properties that contribute to its pharmacological actions and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 57076-71-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,7,0,7 and 6 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 57076-71:
(7*5)+(6*7)+(5*0)+(4*7)+(3*6)+(2*7)+(1*1)=138
138 % 10 = 8
So 57076-71-8 is a valid CAS Registry Number.
InChI:InChI=1/C16H24N4O3/c1-4-6-8-19-14-13(18(11-17-14)10-12(3)21)15(22)20(16(19)23)9-7-5-2/h11H,4-10H2,1-3H3
57076-71-8Relevant articles and documents
Combination preparation for use in dementia
-
, (2008/06/13)
The invention relates to a composition which is a pharmaceutical combination preparation comprising a compound which has an acetylcholinesterase-inhibitory action or exhibits muscarinergic action and a compound which increases the endogenous extracellular adenosine level, wherein the combination preparation is suitable for the treatment of dementia. The invention further relates to a process for the production of the combination preparation. The invention additionally relates to a process for treating patients in need of suitable therapy with the combination preparation.
Xanthine derivatives for the treatment of secondary nerve cell damage and functional disorders after cranio-cerebral traumas
-
, (2008/06/13)
The use of xanthine derivatives for the treatment of secondary nerve cell damage and functional disorders after cranio-cerebral traumas (CCT) The use of xanthine derivatives of the formula I STR1 and of their physiologically tolerable salts, in which R1 is oxoalkyl, hydroxyalkyl or alkyl, R2 is hydrogen or alkyl and R3 is hydrogen, alkyl, oxoalkyl or an alkyl having up to 6 carbon atoms, whose carbon chain is interrupted by an oxygen atom, for the production of pharmaceuticals for the treatment of disorders which can occur after cranio-cerebral traumas is described.
